Yilmaz Mahshid

Yilmaz has experience from different senior positions in the life science sector, including Investment Manager & Controller at Industrifonden, and CFO at PledPharma between 2017 and 2020, as well as healthcare analyst at Pareto Securities and Öhman Fondkommission. Prior to joining Egetis Therapeutics, Yilmaz was CEO of the listed biotech company Medivir.

Yilmaz also has a solid academic background with a PhD from the Department of Medical Biochemistry and Biophysics at Karolinska Institutet, Stockholm.